Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Canaccord Genuity Reiterates Buy on Edwards Lifesciences (EW) following 3Q Results
October 27, 2015 10:50 AM EDTCanaccord Genuity reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $180.00 (from $178.00), following the company's 3Q earnings results. EW reported EPS of $1.07, beating consensus by 9c. Management does an excellent job hedging FX swings to neutralize EPS... More
UBS Raises Price Target on Edwards Lifesciences (EW) Following Strong 3Q Results
October 27, 2015 8:57 AM EDTUBS reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $203.00 (from $201.00), following the company's 3Q15 earnings results. Management upped fullyear EPS guidance by $4.43-4.53 from $4.30-4.40, which assumes a touch more upside in Q4.
Analyst Matt Miksic... More
Edwards Lifesciences (EW) Tops Q3 EPS by 9c, Q4 & FY Guidance Tops Views
October 26, 2015 4:18 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.09 better than the analyst estimate of $0.98. Revenue for the quarter came in at $615 million versus the consensus estimate of $598.29 million.
Edwards Lifesciences sees FY2015 EPS of $4.43-$4.53, versus the consensus of $4.37. Edwards Lifesciences sees FY2015... More
